Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Sofia Halin, Peter Hammarsten, Hani Adamo, Pernilla Wikström & Anders Bergh. (2011) Tumor indicating normal tissue could be a new source of diagnostic and prognostic markers for prostate cancer. Expert Opinion on Medical Diagnostics 5:1, pages 37-47.
Read now
Read now
Stina Häggström Rudolfsson & Anders Bergh. (2009) Hypoxia drives prostate tumour progression and impairs the effectiveness of therapy, but can also promote cell death and serve as a therapeutic target. Expert Opinion on Therapeutic Targets 13:2, pages 219-225.
Read now
Read now
Axel Stachon, Assem Aweimer, Tanja Stachon, Andrea Tannapfel, Sven Thoms, Burkhard Ubrig, Manfred Köller, Michael Krieg & Michael C. Truss. (2009) Secretion of soluble VEGF receptor 2 by microvascular endothelial cells derived by human benign prostatic hyperplasia. Growth Factors 27:2, pages 71-78.
Read now
Read now
Jorge L. Yao, Charlotte K. Ryan, Charles W. Francis, Manish Kohli, Mark B. Taubman & Alok A. Khorana. (2009) Tissue Factor and VEGF Expression in Prostate Carcinoma: A Tissue Microarray Study. Cancer Investigation 27:4, pages 430-434.
Read now
Read now
Articles from other publishers (44)
Linyu Ni, Wei-kuan Lin, Amy Kasputis, Deborah Postiff, Javed Siddiqui, Matthew J. Allaway, Matthew S. Davenport, John T. Wei, Jay L. Guo, Todd M. Morgan, Aaron M. Udager, Xueding Wang & Guan Xu. (2022) Assessment of prostate cancer progression using a translational needle photoacoustic sensing probe: Preliminary study with intact human prostates ex-vivo. Photoacoustics 28, pages 100418.
Crossref
Crossref
Sofia Halin Bergström, Stina H Rudolfsson & Anders Bergh. (2016) Rat Prostate Tumor Cells Progress in the Bone Microenvironment to a Highly Aggressive Phenotype. Neoplasia 18:3, pages 152-161.
Crossref
Crossref
Geoffrey Burnstock & Francesco Di Virgilio. (2013) Purinergic signalling and cancer. Purinergic Signalling 9:4, pages 491-540.
Crossref
Crossref
Juan Wen, Yuan Zhao, Jinghe Li, Chunyan Weng, Jingjing Cai, Kan Yang, Hong Yuan, Julianne Imperato‐McGinley & Yuan‐Shan Zhu. (2013) Suppression of DHT‐induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells. The Prostate 73:10, pages 1069-1081.
Crossref
Crossref
T. Shepherd & R. Owenius. (2012) Gaussian Process Models of Dynamic PET for Functional Volume Definition in Radiation Oncology. IEEE Transactions on Medical Imaging 31:8, pages 1542-1556.
Crossref
Crossref
A Aweimer, T Stachon, A Tannapfel, M Köller, M C Truss & A Stachon. (2011) Regulation of soluble VEGFR-2 secreted by microvascular endothelial cells derived from human BPH. Prostate Cancer and Prostatic Diseases 15:2, pages 157-164.
Crossref
Crossref
Christina Hägglöf & Anders Bergh. (2012) The Stroma—A Key Regulator in Prostate Function and Malignancy. Cancers 4:2, pages 531-548.
Crossref
Crossref
Viviana P. Montecinos, Alejandro Godoy, Jennifer Hinklin, R. Robert Vethanayagam & Gary J. Smith. (2012) Primary Xenografts of Human Prostate Tissue as a Model to Study Angiogenesis Induced by Reactive Stroma. PLoS ONE 7:1, pages e29623.
Crossref
Crossref
Andreas Josefsson, Hani Adamo, Peter Hammarsten, Torvald Granfors, Pär Stattin, Lars Egevad, Anna Engström Laurent, Pernilla Wikström & Anders Bergh. (2011) Prostate Cancer Increases Hyaluronan in Surrounding Nonmalignant Stroma, and This Response Is Associated with Tumor Growth and an Unfavorable Outcome. The American Journal of Pathology 179:4, pages 1961-1968.
Crossref
Crossref
F Gao, M Yang, C Li Luo & X H Wu. (2011) Local insulin-like growth factor-I of ventral prostate was upregulated during long-term castration and may function through the autocrine system. Prostate Cancer and Prostatic Diseases 14:2, pages 136-142.
Crossref
Crossref
Alejandro GodoyViviana P. MontecinosDanny R. Gray, Paula SotomayorJeffrey M. Yau, R. Robert VethanayagamSwaroop SinghJames L. MohlerGary J. Smith. (2011) Androgen deprivation induces rapid involution and recovery of human prostate vasculature. American Journal of Physiology-Endocrinology and Metabolism 300:2, pages E263-E275.
Crossref
Crossref
Sharon D. Morgenbesser. 2011. Tumor Models in Cancer Research. Tumor Models in Cancer Research
397
421
.
Christina Hägglöf, Peter Hammarsten, Andreas Josefsson, Pär Stattin, Janna Paulsson, Anders Bergh & Arne Östman. (2010) Stromal PDGFRβ Expression in Prostate Tumors and Non-Malignant Prostate Tissue Predicts Prostate Cancer Survival. PLoS ONE 5:5, pages e10747.
Crossref
Crossref
Xian-Qing Zhang, Xiao-Feng Huang, Shi-Jie Mu, Qun-Xing An, Ai-Jun Xia, Rui Chen & Dao-Cheng Wu. (2010) Inhibition of proliferation of prostate cancer cell line, PC-3, in vitro and in vivo using (−)-gossypol. Asian Journal of Andrology 12:3, pages 390-399.
Crossref
Crossref
Erin R. Gardner, Giuseppe Di Lorenzo & William D. Figg. 2010. Drug Management of Prostate Cancer. Drug Management of Prostate Cancer
215
223
.
Anders Bergh. (2009) Characterization and functional role of the stroma compartment in prostate tumors. Future Oncology 5:8, pages 1231-1235.
Crossref
Crossref
Sofia Halin, Stina Häggström Rudolfsson, Nico Van Rooijen & Anders Bergh. (2009) Extratumoral Macrophages Promote Tumor and Vascular Growth in an Orthotopic Rat Prostate Tumor Model. Neoplasia 11:2, pages 177-186.
Crossref
Crossref
Sean Foxley, Xiaobing Fan, Devkumar Mustafi, Chad Haney, Marta Zamora, Erica Markiewicz, Milica Medved, Abbie M. Wood & Gregory S. Karczmar. (2009) Sensitivity to tumor microvasculature without contrast agents in high spectral and spatial resolution MR images. Magnetic Resonance in Medicine 61:2, pages 291-298.
Crossref
Crossref
Stefano Iacobelli. (2008) Hormone-refractory prostate cancer responding to bevacizumab. International Journal of Urology 15:8, pages 754-754.
Crossref
Crossref
John T. Isaacs. (2008) Prostate stem cells and benign prostatic hyperplasia. The Prostate 68:9, pages 1025-1034.
Crossref
Crossref
Robert S. Svatek, Jose A. Karam, Claus G. Roehrborn, Pierre I. Karakiewicz, Kevin M. Slawin & Shahrokh F. Shariat. (2008) Preoperative Plasma Endoglin Levels Predict Biochemical Progression After Radical Prostatectomy. Clinical Cancer Research 14:11, pages 3362-3366.
Crossref
Crossref
Jose A. Karam, Robert S. Svatek, Pierre I. Karakiewicz, Andrea Gallina, Claus G. Roehrborn, Kevin M. Slawin & Shahrokh F. Shariat. (2008) Use of Preoperative Plasma Endoglin for Prediction of Lymph Node Metastasis in Patients with Clinically Localized Prostate Cancer. Clinical Cancer Research 14:5, pages 1418-1422.
Crossref
Crossref
Ilke H. Onen, Ece Konac, Muzaffer Eroglu, Cagri Guneri, Hasan Biri & Abdullah Ekmekci. (2007) No association between polymorphism in the vascular endothelial growth factor gene at position−460 and sporadic prostate cancer in the Turkish population. Molecular Biology Reports 35:1, pages 17-22.
Crossref
Crossref
Pernilla Wikström, Nina Ohlson, Pär Stattin & Anders Bergh. (2007) Nuclear androgen receptors recur in the epithelial and stromal compartments of malignant and non‐malignant human prostate tissue several months after castration therapy. The Prostate 67:12, pages 1277-1284.
Crossref
Crossref
Peter Hammarsten, Stina Häggström Rudolfsson, Roger Henriksson, Pernilla Wikström & Anders Bergh. (2007) Inhibition of the epidermal growth factor receptor enhances castration‐induced prostate involution and reduces testosterone‐stimulated prostate growth in adult rats. The Prostate 67:6, pages 573-581.
Crossref
Crossref
Jennifer A. Doll PhD, Jennifer E. Hobbs PhD & Gerald A. Soff MD. 2007. Apoptosis, Senescence, and Cancer. Apoptosis, Senescence, and Cancer
537
555
.
Richard J. Ablin & Malcolm D. Mason. 2007. Metastasis of Prostate Cancer. Metastasis of Prostate Cancer
355
397
.
Nina Ohlson, Anders Bergh, Malin Lindhagen Persson & Pernilla Wikström. (2006) Castration rapidly decreases local insulin-like growth factor-1 levels and inhibits its effects in the ventral prostate in mice. The Prostate 66:16, pages 1687-1697.
Crossref
Crossref
Michael C. Cox, William L. Dahut & William D. Figg. (2006) The use of thalidomide in androgen-independent prostate cancer. Urologic Oncology: Seminars and Original Investigations 24:3, pages 246-249.
Crossref
Crossref
Ugur Ozerdem. (2006) Targeting of pericytes diminishes neovascularization and lymphangiogenesis in prostate cancer. The Prostate 66:3, pages 294-304.
Crossref
Crossref
Wanzhong Wang, Anders Bergh & Jan-Erik Damber. (2005) Cyclooxygenase-2 Expression Correlates with Local Chronic Inflammation and Tumor Neovascularization in Human Prostate Cancer. Clinical Cancer Research 11:9, pages 3250-3256.
Crossref
Crossref
Metin Ozkan, Bulent Eser, Ozlem Er, Gamze Gokoz Dogu & Mustafa Altinbas. (2005) Inhibition of Angiogenesis: Thalidomide or Low-Molecular-Weight Heparin?. Journal of Clinical Oncology 23:9, pages 2113-2113.
Crossref
Crossref
Piotr Kozlowski, Jason Wong & S. Larry Goldenberg. (2005) Serial tumour blood-flow measurements in androgen-dependent and -independent Shionogi tumour models. BJU International 95:4, pages 644-649.
Crossref
Crossref
Fengshuo Jin, Zhihui Xie, Calvin J Kuo, Leland W K Chung & Chia-Ling Hsieh. (2004) Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy. Cancer Gene Therapy 12:3, pages 257-267.
Crossref
Crossref
Anna J:son Lind, Pernilla Wikström, Torvald Granfors, Lars Egevad, Pär Stattin & Anders Bergh. (2004) Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer. The Prostate 62:4, pages 394-399.
Crossref
Crossref
Stephanie J. McAlhany, Gustavo E. Ayala, Anna Frolov, Steven J. Ressler, Thomas M. Wheeler, J.E. Vivienne Watson, Colin Collins & David R. Rowley. (2004) Decreased stromal expression and increased epithelial expression of WFDC1/ps20 in prostate cancer is associated with reduced recurrence‐free survival. The Prostate 61:2, pages 182-191.
Crossref
Crossref
Sofia Halin, Pernilla Wikström, Stina Häggström Rudolfsson, Pär Stattin, Jennifer A. Doll, Susan E. Crawford & Anders Bergh. (2004) Decreased Pigment Epithelium-Derived Factor Is Associated with Metastatic Phenotype in Human and Rat Prostate Tumors. Cancer Research 64:16, pages 5664-5671.
Crossref
Crossref
William L. Dahut, James L. Gulley, Philip M. Arlen, Yinong Liu, Katherine M. Fedenko, Seth M. Steinberg, John J. Wright, Howard Parnes, Clara C. Chen, Elizabeth Jones, Catherine E. Parker, W. Marston Linehan & William D. Figg. (2004) Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer. Journal of Clinical Oncology 22:13, pages 2532-2539.
Crossref
Crossref
Wael A Sakr & M.Scott Lucia. (2004) Potential pathologic markers for prostate chemoprevention studies. Urologic Clinics of North America 31:2, pages 227-235.
Crossref
Crossref
Danny R. Gray, Wendy J. Huss, Jeffrey M. Yau, Lori E. Durham, Eric S. Werdin, William K. FunkhouserJr.Jr. & Gary J. Smith. (2004) Short-Term Human Prostate Primary Xenografts. Cancer Research 64:5, pages 1712-1721.
Crossref
Crossref
Yoshihiro Ono, Kazuhiro Suzuki, Bunzo Kashiwagi, Yasuhiro Shibata, Kazuto Ito, Yoshitatsu Fukabori & Hidetoshi Yamanaka. (2004) Androgen-dependent blood flow control and morphological changes of the capillaries in rat prostate. International Journal of Andrology 27:1, pages 50-56.
Crossref
Crossref
Ingela Franck Lissbrant, Peter Hammarsten, Erik Lissbrant, Napoleone Ferrara, Stina Häggström Rudolfsson & Anders Bergh. (2003) Neutralizing VEGF bioactivity with a soluble chimeric VEGF‐receptor protein flt(1‐3)IgG inhibits testosterone‐stimulated prostate growth in castrated mice. The Prostate 58:1, pages 57-65.
Crossref
Crossref
Avi S. Retter, William D. Figg & William L. Dahut. (2003) The Combination of Antiangiogenic and Cytotoxic Agents in the Treatment of Prostate Cancer. Clinical Prostate Cancer 2:3, pages 153-159.
Crossref
Crossref
Hui Wang, Dong Yu, Sudhir Agrawal & Ruiwen Zhang. (2002) Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed‐backbone antisense oligonucleotides: In vitro and in vivo activities and mechanisms. The Prostate 54:3, pages 194-205.
Crossref
Crossref